Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

Andrea Bacigalupo, Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin, Giovanna Piaggio, Francesca Bertolotti

Research output: Contribution to journalArticlepeer-review


Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p

Original languageEnglish
Pages (from-to)42-44
Number of pages3
JournalRevista Brasileira de Hematologia e Hemoterapia
Issue numberSUPPL. 2
Publication statusPublished - Jun 2008


  • Acute lymphoid leukemia
  • Acute myeloid leukemia
  • Allogeneic hematopoietic stem cell transplantation
  • Donor lymphocyte infusion
  • Minimal residual disease

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia'. Together they form a unique fingerprint.

Cite this